Travel to low- and middle-income countries and travellers’ diarrhoea increase risk of mismatching antimicrobial therapy for urinary tract infection

LMIC travel increases the risk of nonmatching empiric antimicrobials, concurring with increased trimethoprim resistance rates amongst the non-ESBL-PE isolates. Our data suggest that UTI patients with recent LMIC travel should not be empirically treated with trimethoprim and, when possible, urinary culturing is warranted.